Updated Jul 16, 2026
RODRIGUEZ RAUL R has filed 2 SEC Form 4 filings across 1 company in the last 90 days.
Raul R. Rodriguez is the CEO and President of Rigel Pharmaceuticals Inc, a company focused on developing small-molecule drugs for various diseases. Under his leadership, Rigel has advanced its pipeline, including the oral rheumatoid arthritis drug candidate licensed to AstraZeneca.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-03 | RIGL | RIGEL PHARMACEUTICALS INC | F — Tax withholding / forfeiture | 2.4K | $29.86 | $72K |
| 2026-02-19 | RIGL | RIGEL PHARMACEUTICALS INC | A — Grant or award | 53.9K | $0.00 | |
| 2026-02-12 | RIGL | RIGEL PHARMACEUTICALS INC | F — Tax withholding / forfeiture | 7.6K | $34.62 | $263K |
| 2026-02-04 | RIGL | RIGEL PHARMACEUTICALS INC | F — Tax withholding / forfeiture | 14.1K | $36.01 | $508K |
| 2026-02-04 | RIGL | RIGEL PHARMACEUTICALS INC | F — Tax withholding / forfeiture | 35.4K | $37.00 | $1.31M |
| 2026-02-04 | RIGL | RIGEL PHARMACEUTICALS INC | M — Option exercise | 40.0K | $27.40 | $1.10M |
| 2026-02-04 | RIGL | RIGEL PHARMACEUTICALS INC | F — Tax withholding / forfeiture | 35.2K | $37.00 | $1.30M |
| 2026-02-04 | RIGL | RIGEL PHARMACEUTICALS INC | M — Option exercise | 40.0K | $27.40 | $1.10M |
Raul R. Rodriguez is the CEO and President of Rigel Pharmaceuticals Inc, a company focused on developing small-molecule drugs for various diseases. Under his leadership, Rigel has advanced its pipeline, including the oral rheumatoid arthritis drug candidate licensed to AstraZeneca.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live RODRIGUEZ RAUL R profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.